A randomized, phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men.

BI 764198 - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/40402558

Akiko Sarashina; Nima Soleymanlou; Silke Retlich; Takuma Yonemura; Yoshifumi Tachibana

May 22, 2025